Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Cortex Pharmaceuticals Inc. (RSPI) had Normalized Income after Taxes of $-0.40M for the most recently reported fiscal quarter, ending 2023-09-30.
| Income Statement Financials | |
-- |
|
$-0.41M |
|
-- |
|
-- |
|
$0.33M |
|
$-0.33M |
|
$-0.06M |
|
$-0.40M |
|
$-0.40M |
|
$-0.40M |
|
$-0.40M |
|
$-0.40M |
|
|
Normalized Income after Taxes |
$-0.40M |
$-0.33M |
|
$-0.21M |
|
267.73M |
|
267.73M |
|
$-0.00 |
|
$-0.00 |
|
| Balance Sheet Financials | |
$0.11M |
|
-- |
|
-- |
|
$0.11M |
|
$12.06M |
|
-- |
|
$0.34M |
|
$12.41M |
|
$-13.11M |
|
$-12.30M |
|
$-12.30M |
|
298.33M |
|
| Cash Flow Statement Financials | |
$-0.26M |
|
-- |
|
$0.27M |
|
$0.00M |
|
$0.01M |
|
$0.01M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.01 |
|
-- |
|
-- |
|
-- |
|
-0.23 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.26M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
3.02% |
|
3.22% |
|
-363.97% |
|
3.22% |
|
$-0.04 |
|
$-0.00 |
|
$-0.00 |
|